PitchSend

Investor Presentaiton

Basic Policy 1: Continuous strengthening of our base in existing businesses 3 Healthcare Business expansion Strengthening profitability in Pharmaceutical Purification Materials / APIs and their intermediates by capturing the growing demand in recent years Increase production capacity in preparation for future strong demand Business environment (million of yen) 12,000 (million of yen) 20,000 I Net sales (left scale) Opretaring income (right scale) 16,500 9,000 Pharmaceutical Purification Material Diabetes medications (including GLP-1 receptor agonists) grows at an annual rate of 10% 15,000 Obesity medications continue to high growth potential ● Expect to biosimilars enter the market 10,275 Growth of purification separation materials market for medium-molecular drugs 10,000 6,000 8,224 6,000 Global pharmaceutical market expands at an annual rate of 3-6% 4,615 5,000 3,000 3,375 APIs and intermediates ● Accelerating the return of procurement to Japan in APIs and intermediates due to quality issues and stricter environmental regulations Development of medium-molecular drugs is progressing 0 0 FY2021* FY2022* FY2025 (Target) * figures reclassified into new segments Important measures [Pharmaceutical Purification Materials] Capture growing Slica gel demand Become the global de facto standard by strengthen global operations and branding Expand production capacity to meet future demand increases Development and commercialization of Polymer gel [APIs and their intermediates] Fully operate of new facility "PI-3" Implementation of next facility enhancements Strengthening the high-potency pharmaceutical business Advance into the biopharmaceutical business Something Better with Chemicals OSAKA SODA 25

View entire presentation